Clinical trial · no report yet · Phase 3

FORAGER-2 trial: what clinicians have said so far

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

NCT07218380 ↗
Recruiting
Eli Lilly and Company
Standard size, estimated: 151–300 verified statements

We haven't built an HCP commentary report on FORAGER-2 (vepugratinib plus enfortumab vedotin plus pembrolizumab) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on FORAGER-2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Indexed so far
14 posts on X
3 videos on X
2 podcast episodes
1 YouTube video

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration
Phase: Phase 3
Status: Recruiting
Conditions: Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Neoplasm Metastasis
Interventions: Vepugratinib; Placebo; EV; Pembrolizumab
Arms: Vepugratinib + EV + Pembrolizumab (Safety Lead In) · Experimental
Vepugratinib + Enfortumab Vedotin (EV) + Pembrolizumab · Experimental
Placebo + EV + Pembrolizumab · Placebo comparator
Enrollment: 450 (estimated)
Primary outcomes: Number of participants with treatment-related adverse events related to vepugratinib in combination with EV and pembrolizumab
Safety Lead-in: Overall Response Rate (ORR)
Progression-free Survival (PFS)
Sponsor: Eli Lilly and Company
Start: Dec 12, 2025
Primary completion: Oct 2029 (estimated)
Results posted: No
Registry record: NCT07218380 · updated Oct 7, 2026

Get this report

Standard

Report, built on orderBuilt within 24 hours of confirming your order: $1,250

Order this report

Quoted on an estimate of the verified statements in the commentary we've indexed so far. Final coverage is set when we build it.You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded.We build it within 24 hours of confirming your order. If we can't build it to our standard, you aren't charged.

Request a free preview

Ask us to build this report. Once it's built, its free preview (summary, finding titles and coverage) is published on this page and we email you the link. The full report is sold separately. Use your work email; we'll send a link to confirm it.

For agents: .json · .md

Indexed commentary on FORAGER-2 so far

Reports on the same drug or indication

The trial